




Figure 1. CV1 antibody binding to *Aspergillus* spp implies the presence of a CD47 structural mimic (mCD47). **A.** representative positive and negative staining for CV1. **B.** Size and morphology of *Aspergillus* stages of growth and human alveolar macrophages. **C.** *Aspergillus fumigatus* (Af) binding to CV1 antibody during growth stages. **D.** *Aspergillus fumigatus*, *terreus*, *flavus*, *niger*, *nidulans* conidia binding to CV1 antibody.





Figure 2. CV1 antibody binding to *Af* surface protein mutants and investigation of macrophages phagocytosis of these mutants. **A.** CV1 binding to *Af* mutant strains Δ RodA, Δ pksP, Δ DDPV, Δ pksP complement, Δ Aspf3, **B.** Macrophages ingestion of *Af* strains with or with CV1 coating. **C.** CV1 binding to *Af* melanin mutants. **D.** Macrophages ingestion of *Af* melanin-mutant strains.



C.

Figure 3. *Aspergillus* melanin binding to SIRPα **A.** *In silico* docking of *Aspergillus* melanin forms and human SIRPα. **B.** Confocal microscopy imaging of SIRPα binding to *Aspergillus* conidia. **C.** Surface plasmon resonance image of *Aspergillus* melanin-complement strain binding to human SIRPα protein.




Figure 4. *Aspergillus* melanin and SIRPα complex biochemical analysis. **A.** SDS page. **B.** HPLC.